Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
21 May, 2019 17:18 IST
Glenmark Pharma gets tentative ANDA nod for Fulvestrant injection
Source: IRIS | 07 Feb, 2019, 10.25AM
Comments  |  Post Comment

Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted tentative approval by the United States Food & Drug Administration (U.S. FDA) for Fulvestrant Injection, 250 mg/5 mL (50 mg/mL), a generic version of FASLODEX 1 Injection, 250 mg/5 mL (50 mg/mL), of AstraZeneca Pharmaceuticals LP.

According to IQVIATM sales data for the 12 month period ending December 2018, the FASLODEX Injection, 250 mg/5 mL (50 mg/mL) market2 achieved annual sales of approximately USD 533.3 million.
 
Glenmark's current portfolio consists of 148 products authorized for distribution in the U.S. marketplace and 54 ANDA's pending approval with the U.S. FDA. In addition to these internal filings, Glenmark (Q,N,C,F)* continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.

Shares of the company gained Rs 3.25, or 0.51%, to trade at Rs 644.00. The total volume of shares traded was 2,068 at the BSE (9.25 a.m., Thursday).

Comments Post comment 
 Post Comment
Name Email
Comment
Security Code type    into this box
Company Update
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer